eFFECTOR Therapeutics Inc...

0.00
-0.00 (-100.00%)
At close: Mar 06, 2025, 9:31 AM
0.00
0.00%
After-hours: Apr 01, 2025, 04:00 PM EDT
-100.00%
Bid n/a
Market Cap 941
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -12.57
PE Ratio (ttm) n/a
Forward PE n/a
Analyst Buy
Ask n/a
Volume 400
Avg. Volume (20D) 971
Open 0.00
Previous Close 0.00
Day's Range 0.00 - 0.00
52-Week Range 0.00 - 16.88
Beta 0.54

About EFTR

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit euk...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 1, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol EFTR
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for EFTR stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 11999900.00% from the latest price.

Stock Forecasts
9 months ago
-75.81%
EFFECTOR Therapeutics shares are trading lower aft... Unlock content with Pro Subscription